^
BIOMARKER:

CD44 overexpression + CD24 underexpression

i
Other names: CD24, CD24 Molecule, CD24 Antigen (Small Cell Lung Carcinoma Cluster 4 Antigen), Signal Transducer CD24, CD24A, Small Cell Lung Carcinoma Cluster 4 Antigen, CD24 Antigen, CD44, CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Entrez ID:
Related biomarkers:
4ms
P=N/A, N=68, Active, not recruiting, Mayo Clinic | Suspended --> Active, not recruiting | N=250 --> 68 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • CD44 • CDH1 (Cadherin 1) • CD24 (CD24 Molecule) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2) • FOXP3 (Forkhead Box P3)
|
ER positive • HER-2 negative • CD44 overexpression + CD24 underexpression • ER-L
|
Ibrance (palbociclib)
over1year
Clinical • Trial suspension • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • CD44 • CDH1 (Cadherin 1) • CD24 (CD24 Molecule) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2) • FOXP3 (Forkhead Box P3)
|
ER positive • HER-2 negative • CD44 overexpression + CD24 underexpression • ER-L
|
Ibrance (palbociclib)